Original Article
Brief Report
Codeine Intoxication Associated with Ultrarapid CYP2D6 Metabolism
N Engl J Med 2004; 351:2827-2831December 30, 2004
- Abstract
Life-threatening opioid intoxication developed in a patient after he was given small doses of codeine for the treatment of a cough associated with bilateral pneumonia. Codeine is bioactivated by CYP2D6 into morphine, which then undergoes further glucuronidation. CYP2D6 genotyping showed that the patient had three or more functional alleles, a finding consistent with ultrarapid metabolism of codeine. We attribute the toxicity to this genotype, in combination with inhibition of CYP3A4 activity by other medications and a transient reduction in renal function.
Media in This Article
Figure 1
Metabolic Pathways of Codeine Biotransformation.Article Activity
- Article
Adverse drug reactions are a major cause of death in hospitalized patients.1 Differences among persons in the level of cytochrome P-450–dependent monooxygenase activity may lead to differences in the efficacy and toxicity of drugs metabolized by this enzyme system.2-4
Cytochrome P-450 is the product of a multigene family, and its activity may reflect drug–drug interaction. Genetic variants of the cytochrome P-450 enzyme CYP3A4 are relatively common, but to our knowledge none of them have been shown to cause a phenotypic change in drug metabolism. In contrast, various genotypes of the CYP2D6 subfamily of cytochrome P-450 enzymes correlate with phenotypic subgroups with differing rates of drug metabolism.5,6 A person with two nonfunctional alleles at CYP2D6 is considered to have poor drug metabolism, whereas a person with one or two functional alleles is considered to have extensive metabolism, and one who has duplicated or amplified active CYP2D6 genes is considered to have ultrarapid metabolism.7 About 7 to 10 percent of whites have poor CYP2D6 metabolism, whereas 1 to 7 percent of whites and more than 25 percent of Ethiopians have gene duplications and are classified as having ultrarapid metabolism. CYP2D6 catalyzes hydroxylation or demethylation of more than 20 percent of drugs, including codeine.
O-demethylation of codeine into morphine by CYP2D6 represents a minor pathway of codeine metabolism (accounting for less than 10 percent of codeine clearance)8 but is essential for its opioid activity (Figure 1Figure 1
Metabolic Pathways of Codeine Biotransformation.). N-demethylation of codeine into norcodeine by CYP3A4 and the glucuronidation of codeine are the main pathways (accounting for more than 80 percent of codeine clearance) for converting the molecule into inactive compounds.We describe a patient who presented with life-threatening codeine intoxication despite having received only modest doses of the medication. Analysis of the patient's cytochrome P-450–dependent monooxygenase genotype (CYP2D6) and phenotype (CYP2D6 and CYP3A4) indicated that his unusual response to codeine might be explained by ultrarapid CYP2D6 metabolism, combined with the inhibition of CYP3A4 by other medications and the accumulation of active metabolites because of renal failure.
Case Report
A 62-year-old man with a history of chronic lymphocytic leukemia presented with a three-day history of fatigue, dyspnea, fever, and a cough. He had last received chemotherapy three months earlier. His only medication was valproic acid (1500 mg daily), which he had been taking for several years after he had had a post-traumatic generalized seizure. On arrival at the hospital, the patient was alert and oriented and was hypoxemic (partial pressure of arterial oxygen, 56 mm Hg; fraction of inspired oxygen, 0.21) but normocapnic (partial pressure of arterial carbon dioxide, 37 mm Hg). Clinical and radiologic findings were compatible with bilateral pneumonia limited to the inferior lobes. Because of his immunocompromised state, bronchoalveolar lavage was performed. Preliminary results showed no Pneumocystis carinii but revealed yeast. Therapy with ceftriaxone, clarithromycin, and voriconazole was initiated, and oral codeine (25 mg three times a day) was administered to relieve the cough.
On hospital day 4, the patient's level of consciousness rapidly deteriorated, and he became unresponsive. His last dose of codeine had been administered 12 hours earlier. Arterial blood gas measurements revealed a partial pressure of oxygen of 56 mm Hg, with a fraction of inspired oxygen of 0.5 and a partial pressure of carbon dioxide of 80 mm Hg. The patient was treated with noninvasive ventilation and was transferred to the intensive care unit. Initial neurologic examination showed a score of 6 on the Glasgow Coma Scale (no eye opening, no verbal response, and limb withdrawal after pain stimulation). The patient's pupils were miotic, and no focal deficits were detected.
Ninety minutes after the initiation of noninvasive ventilation, repeated measurements of arterial blood gases showed that the partial pressure of oxygen was 68 mm Hg and the partial pressure of carbon dioxide was 56 mm Hg, but no neurologic improvement was observed. The serum urea nitrogen and creatinine levels were elevated, at 45.4 mg per deciliter (16.2 mmol per liter) and 2.06 mg per deciliter (182 μmol per liter), respectively; the levels subsequently normalized with hydration. The serum level of valproic acid was 62.4 mg per liter (433 μmol per liter; normal range, 50.4 to 101 mg per liter [350 to 700 μmol per liter]) on the patient's usual dosage. The blood level of ammonia was normal. Intravenous administration of naloxone (0.4 mg) that was repeated two times resulted in a dramatic improvement in the patient's level of consciousness; with titration of naloxone (a continuous perfusion of 0.4 mg per hour for six hours), a normal level of consciousness was maintained and respiratory failure resolved. Two days after the acute event, the patient had recovered completely.
Methods
The blood levels of codeine, morphine, and their metabolites were determined by liquid chromatography–mass spectrometry.9 Duplication or multiduplication of the CYP2D6 gene was detected by restriction-fragment–length polymorphism analysis of genomic DNA isolated from leukocytes, after digestion with restriction enzymes XbaI and EcoRI, as described elsewhere.6,10 The CYP2D6 and CYP3A4 phenotype was also determined. The widely used dextromethorphan substrate was used as a probe drug to evaluate CYP phenotypic activity. In humans, dextromethorphan is metabolized into dextrorphan by CYP2D6 and into 3-methoxymorphinan, mainly by CYP3A4. Moreover, 3-hydroxymorphinan is obtained through N- and O-didemethylation by CYP3A4 and CYP2D6, respectively. Hence, the partial metabolic clearance of dextromethorphan to the O-demethylated metabolites can be used as an index of CYP2D6 activity, whereas the partial metabolic clearance of dextromethorphan to the N-demethylated metabolites can be used as an index of CYP3A4 activity, as described by Di Marco et al.11
To assess the relative activities of CYP2D6 and CYP3A4, we used both a traditional method based on a metabolic-ratio calculation obtained by dividing the amount of dextromethorphan by the amount of deconjugated dextrorphan excreted in urine (for CYP2D6) and a partial metabolic-clearance approach as described above. According to a standardized protocol, a single 25-mg oral dose of dextromethorphan was administered to our patient seven days after his discharge from the intensive care unit, after complete recovery of renal function but while he was still receiving clarithromycin and voriconazole. We used high-performance liquid chromatography to assay deconjugated dextromethorphan and its metabolites in a hydrolyzed urine specimen obtained in the eight hours after the dose of dextromethorphan had been administered.
The patient provided oral consent for testing and for publication of the report. Our institutional review board did not require written consent because the investigation was considered to be part of clinical care.
Results
At the time of the patient's coma and respiratory depression, the plasma level of codeine was 114 μg per liter, as compared with a maximal expected plasma level in the range of 13 to 75 μg per liter for the same dose in a person with extensive CYP2D6 metabolism.12 The codeine glucuronide level was 361 μg per liter (expected range in extensive CYP2D6 metabolism, 700 to 1670 μg per liter), the blood level of morphine was 80 μg per liter (expected range, 1 to 4 μg per liter), the morphine-3-glucuronide level was 580 μg per liter (expected range, 8 to 70 μg per liter), and the morphine-6-glucuronide level was 136 μg per liter (expected range, 1 to 13 μg per liter). Among these metabolites, only morphine and morphine-6-glucuronide have clinically relevant opioid activity.
CYP2D6 genotyping showed three or more functional alleles, a finding consistent with ultrarapid metabolism. Eight hours after the administration of dextromethorphan, the level of the drug in the patient's urine was below the detection limit of the assay (10 ng per milliliter). Thus, the ratio of the amount of dextromethorphan to that of dextrorphan in urine was less than 0.0005, a finding that is compatible with an ultrarapid-metabolism phenotype. As previously described for CYP2D6 phenotyping,13 a logarithmic scale can be used to classify the various types of CYP2D6 metabolism. Ultrarapid metabolism is characterized by a ratio of dextromethorphan to dextrorphan that is below 0.003, extensive metabolism by a ratio between 0.003 and 0.03, intermediate metabolism by a ratio between 0.03 and 0.3, and poor metabolism by a ratio above 0.3.
The phenotype of ultrarapid CYP2D6 metabolism was confirmed by calculation of the partial metabolic clearance related to O-demethylation of dextromethorphan, with a value of 0.48 indicating a high level of production of dextromethorphan metabolites through the CYP2D6 pathway. CYP3A4 activity was evaluated by calculation of the partial metabolic clearance related to N-demethylation of dextromethorphan; the value was 0.04, which is below the mean (±SD) calculated metabolic clearance in healthy volunteers (0.14±0.04).12
Discussion
We describe a patient in whom opioid intoxication occurred after the administration of small doses of codeine, a condition that was attributable to a CYP2D6 ultrarapid-metabolism genotype and phenotype, in combination with drug-induced inhibition of CYP3A4 activity and a reduction in renal function.
Codeine is ineffective at usual doses in 7 to 10 percent of the white population because of homozygosity for nonfunctional mutant CYP2D6 alleles.2 On the other hand, among persons who have ultrarapid metabolism, codeine intake may result in an increase in morphine production. An inverse correlation is expected between the ratio of dextromethorphan to dextrorphan and the amount of O-demethylated codeine metabolites (i.e., morphine, morphine-3-glucuronide, and morphine-6-glucuronide). The concentration of O-demethylated metabolites can be as much as 45 times as high in persons with ultrarapid CYP2D6 metabolism as it is in those with poor metabolism.14 In our patient, the metabolic ratio of dextromethorphan to dextrorphan was extremely low, and 12 hours after the last dose of codeine, the blood level of morphine was 20 to 80 times as high as the blood level that would have been expected on the basis of measurements in healthy persons with extensive CYP2D6 metabolism.12
Along with CYP2D6 gene duplication, a drug–drug interaction may have contributed to the observed toxic effects in our patient. In addition to undergoing O-demethylation into morphine, codeine is N-demethylated into norcodeine by CYP3A4 and also undergoes glucuronidation14 (Figure 1). Our patient was concomitantly treated with a macrolide and an azole derivative, both known inhibitors of CYP3A4. These agents thus may have further reduced the clearance of codeine and increased the risk of an opioid overdose associated with the CYP2D6 gene duplication. Phenotyping with dextromethorphan N-demethylation confirmed the low activity of CYP3A4, whereas the CYP2D6 phenotype was consistent with the CYP2D6 ultrarapid-metabolism genotype. Norcodeine was not detected in the blood, and the level of codeine-6-glucuronide, an inactive metabolite of codeine, was only one third of the expected blood level after repeated administration of oral codeine under normal conditions.12
The opioid effects of codeine are related to plasma morphine concentrations produced after codeine intake. In our patient, blood concentrations of morphine metabolites, morphine-3-glucuronide, and morphine-6-glucuronide were substantially elevated, a finding likely to be attributable to renal failure; morphine-6-glucuronide has recognized opioid activity.15,16 The total amount of morphine and metabolites in our patient corresponded to 75 percent of the total amount of codeine present in his body, whereas the usual amount of morphine that is produced after the administration of multiple doses of codeine rarely reaches 10 percent of the total amount of codeine in a person with extensive CYP2D6 metabolism.12
This report of central nervous system depression after the administration of small doses of codeine in a patient with a CYP2D6 ultrarapid-metabolism phenotype supports the potential usefulness of the determination of genotype and phenotype in elucidating serious adverse drug reactions and in preventing subsequent inappropriate selection or doses of drugs.
Source Information
From the Divisions of Surgical (Y.G., S.C.) and Medical Intensive Care (Y.G.), Clinical Pharmacology and Toxicology (Y.D., P.D., J.D.), and Clinical Chemistry (M.F., A.C.), Geneva University Hospital, Geneva.
Address reprint requests to Dr. Gasche at the Division of Surgical Intensive Care, Department of Anesthesiology, Pharmacology, and Surgical Intensive Care, Geneva University Hospital, 24 rue Micheli-du-Crest, CH-1211 Geneva, Switzerland, or at yvan.gasche@medecine.unige.ch.
- References
References
1
Lazarou J ,Pomeranz BH ,Corey PN . Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205
CrossRef | Web of Science | Medline2
Desmeules J ,Gascon MP ,Dayer P ,Magistris M . Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991;41:23-26
CrossRef | Web of Science | Medline3
Sindrup SH ,Brosen K . The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995;5:335-346
CrossRef | Medline4
Caraco Y ,Sheller J ,Wood AJ . Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther 1999;290:413-422
Web of Science | Medline5
Meyer UA . Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667-1671
CrossRef | Web of Science | Medline6
Johansson I ,Lundqvist E ,Bertilsson L ,Dahl ML ,Sjoqvist F ,Ingelman-Sundberg M . Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90:11825-11829
CrossRef | Web of Science | Medline7
Dahl ML ,Johansson I ,Bertilsson L ,Ingelman-Sundberg M ,Sjoqvist F . Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-520
Web of Science | Medline8
Dayer P ,Desmeules J ,Leemann T ,Stri-berni R . Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 1988;152:411-416
CrossRef | Web of Science | Medline9
Schanzle G ,Li S ,Mikus G ,Hofmann U . Rapid, highly sensitive method for the determination of morphine and its metabolites in body fluids by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 1999;721:55-65
CrossRef | Medline10
Muller B ,Zopf K ,Bachofer J ,Steimer W . Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin Chem 2003;49:1624-1631
CrossRef | Web of Science | Medline11
Di Marco MP ,Edwards DJ ,Wainer IW ,Ducharme MP . The effect of grapefruit juice and Seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 2002;71:1149-1160
CrossRef | Web of Science | Medline12
Yue QY ,Hasselstrom J ,Svensson JO ,Sawe J . Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1991;31:635-642
Web of Science | Medline13
Bertilsson L ,Dahl ML ,Dalen P ,Al-Shurbaji A . Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-122
CrossRef | Web of Science | Medline14
Yue QY ,Alm C ,Svensson JO ,Sawe J . Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Ther Drug Monit 1997;19:539-542
CrossRef | Web of Science | Medline15
Sawe J ,Odar-Cederlof I . Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol 1987;32:377-382
CrossRef | Web of Science | Medline16
Osborne R ,Joel S ,Slevin ML . Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) 1986;292:1548-1549
CrossRef | Web of Science | Medline
- Citing Articles (143)
Citing Articles
1
Michael Camilleri. (2012) The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nature Reviews Gastroenterology & Hepatology
CrossRef2
R. Landau, L. A. Bollag, J. C. Kraft. (2012) Pharmacogenetics and anaesthesia: the value of genetic profiling. Anaesthesia 67:2, 165-179
CrossRef3
Ulrich M. Zanger. 2012. Cytochrome P450 Polymorphisms. .
CrossRef4
Joachim Frost, Arne Helland, Ivar S. Nordrum, Lars Slørdal. (2012) Investigation of morphine and morphine glucuronide levels and cytochrome P450 isoenzyme 2D6 genotype in codeine-related deaths. Forensic Science International
CrossRef5
K R Crews, A Gaedigk, H M Dunnenberger, T E Klein, D D Shen, J T Callaghan, E D Kharasch, T C Skaar. (2011) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype. Clinical Pharmacology & Therapeutics
CrossRef6
Andrew A. Monte, Kennon J. Heard, Vasilis Vasiliou. (2011) Prediction of Drug Response and Safety in Clinical Practice. Journal of Medical Toxicology
CrossRef7
C. Narjoz, C. Moreau, P. Beaune, M. -A. Loriot. (2011) Intérêt clinique de la pharmacogénétique : anticiper les toxicités et mieux prédire l’efficacité des médicaments. Réanimation
CrossRef8
Cheol Kyu Hwang, Yadav Wagley, Ping-Yee Law, Li-Na Wei, Horace H. Loh. (2011) MicroRNAs in Opioid Pharmacology. Journal of Neuroimmune Pharmacology
CrossRef9
Jennifer L. Pilgrim, Dimitri Gerostamoulos, Olaf H. Drummer. (2011) Deaths involving contraindicated and inappropriate combinations of serotonergic drugs. International Journal of Legal Medicine 125:6, 803-815
CrossRef10
Lara Magro, Ugo Moretti, Roberto Leone. (2011) Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert Opinion on Drug Safety1-12
CrossRef11
Eliezer J. Barreiro, Arthur E. Kümmerle, Carlos A. M. Fraga. (2011) The Methylation Effect in Medicinal Chemistry. Chemical Reviews 111:9, 5215-5246
CrossRef12
Jo-Anne Clarke, Murray Cutler, Inna Gong, Ute I. Schwarz, David Freeman, Monidipa Dasgupta. (2011) Cytochrome P450 2D6 Phenotyping in an Elderly Population With Dementia and Response to Galantamine in Dementia: A Pilot Study. The American Journal of Geriatric Pharmacotherapy 9:4, 224-233
CrossRef13
Wojciech Leppert. (2011) Pain Management in Patients with Cancer: Focus on Opioid Analgesics. Current Pain and Headache Reports 15:4, 271-279
CrossRef14
Saskia N de Wildt. (2011) Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opinion on Drug Metabolism & Toxicology 7:8, 935-948
CrossRef15
Ana de Castro, Hendreé E Jones, Rolley E Johnson, Teresa R Gray, Diaa M Shakleya, Marilyn A Huestis. (2011) Methadone, Cocaine, Opiates, and Metabolite Disposition in Umbilical Cord and Correlations to Maternal Methadone Dose and Neonatal Outcomes. Therapeutic Drug Monitoring 33:4, 443-452
CrossRef16
Delphine Allorge, Gilles Tournel. 2011. Role of Pharmacogenetics in Forensic Toxicology. , 133-153.
CrossRef17
T. Krämer. (2011) Pharmakogenetik in der Rechtsmedizin. Rechtsmedizin 21:3, 233-244
CrossRef18
Jörn Lötsch. (2011) Genetic variability of pain perception and treatment—clinical pharmacological implications. European Journal of Clinical Pharmacology 67:6, 541-551
CrossRef19
Kishor Gandhi, James W. Heitz, Eugene R. Viscusi. (2011) Challenges in Acute Pain Management. Anesthesiology Clinics 29:2, 291-309
CrossRef20
Nell Tharpe. (2011) Adverse Drug Reactions in Women's Health Care. Journal of Midwifery & Women's Health 56:3, 205-213
CrossRef21
Caroline Flora Samer, Pierre Dayer, Jules Alexandre Desmeules. (2011) How close are we to individual analgesic adjustment according to a patient’s genotype?. Personalized Medicine 8:3, 289-292
CrossRef22
Judith A. Paice, Betty Ferrell. (2011) The management of cancer pain. CA: A Cancer Journal for Clinicians 61:3, 157-182
CrossRef23
Michael A. Pacanowski, Issam Zineh. (2011) Pharmacogenomic strategies in drug safety. Drug Discovery Today: Therapeutic Strategies
CrossRef24
Jane P. F. Bai, Mike Pacanowski, Atiqur Rahman, Lawrence L. Lesko. 2011. The Impact of Pharmacogenetics on the Clinical Outcomes of Prodrugs. , 453-481.
CrossRef25
I. Johansson, M. Ingelman-Sundberg. (2011) Genetic Polymorphism and Toxicology--With Emphasis on Cytochrome P450. Toxicological Sciences 120:1, 1-13
CrossRef26
Markus R Meyer, Hans H Maurer. (2011) Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics 12:2, 215-233
CrossRef27
Eric R Gamazon, R Stephanie Huang, M Eileen Dolan, Nancy J Cox. (2011) Copy number polymorphisms and anticancer pharmacogenomics. Genome Biology 12:5, R46
CrossRef28
Audun Stubhaug. (2011) Redheads, pain mechanisms and genetics: Lessons learned from inconclusive studies. Scandinavian Journal of Pain 2:1, 1-2
CrossRef29
Howard S. Smith. (2011) The Metabolism of Opioid Agents and the Clinical Impact of Their Active Metabolites. The Clinical Journal of Pain 27:9, 824-838
CrossRef30
Wojciech Leppert. (2011) CYP2D6 in the Metabolism of Opioids for Mild to Moderate Pain. Pharmacology 87:5-6, 274-285
CrossRef31
Alan HB Wu. (2011) Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clinical Proteomics 8:1, 12
CrossRef32
Andrew N. Stevenson, Charles M. Myer, Matthew D. Shuler, Peter S. Singer. (2011) Complications and legal outcomes of tonsillectomy malpractice claims. The Laryngoscopen/a-n/a
CrossRef33
Catherine Litalien, Pierre Beaulieu. 2011. Molecular Mechanisms of Drug Actions. , 1553-1568.
CrossRef34
F. Wickham Kraemer. (2010) Treatment of Acute Pediatric Pain. Seminars in Pediatric Neurology 17:4, 268-274
CrossRef35
Steven W Paugh, Gabriele Stocco, William E Evans. (2010) Pharmacogenomics in pediatric leukemia. Current Opinion in Pediatrics 22:6, 703-710
CrossRef36
Frank Musshoff, Ulrike M. Stamer, Burkhard Madea. (2010) Pharmacogenetics and forensic toxicology. Forensic Science International 203:1-3, 53-62
CrossRef37
Maren Kleine-Brueggeney, Frank Musshoff, Frank Stuber, Ulrike M. Stamer. (2010) Pharmacogenetics in palliative care. Forensic Science International 203:1-3, 63-70
CrossRef38
A. Sajantila, J.U. Palo, I. Ojanperä, C. Davis, B. Budowle. (2010) Pharmacogenetics in medico-legal context. Forensic Science International 203:1-3, 44-52
CrossRef39
P Madadi, Y Joly, D Avard, D C Chitayat, M A Smith, C J D Ross, B C Carleton, M R Hayden, G Koren. (2010) Communicating Pharmacogenetic Research Results to Breastfeeding Mothers Taking Codeine: A Pilot Study of Perceptions and Benefits. Clinical Pharmacology & Therapeutics 88:6, 792-795
CrossRef40
Andrew Parkinson, Brian W. Ogilvie, Brandy L. Paris, Tiffini N. Hensley, Greg J. Loewen. 2010. Human Biotransformation. , 1-77.
CrossRef41
Y J Blumenfeld, M F Reynolds-May, R B Altman, Y Y El-Sayed. (2010) Maternal–fetal and neonatal pharmacogenomics: a review of current literature. Journal of Perinatology 30:9, 571-579
CrossRef42
Sarah Tomasello. (2010) Central Nervous System Medications. Seminars in Dialysis 23:5, 469-472
CrossRef43
Ann K. Daly. (2010) Pharmacogenetics and human genetic polymorphisms. Biochemical Journal 429:3, 435-449
CrossRef44
Geoffrey K Isbister, Felicity Prior, Henry A Kilham. (2010) Restricting cough and cold medicines in children. Journal of Paediatrics and Child Healthno-no
CrossRef45
Ulrike M Stamer, Lan Zhang, Frank Stüber. (2010) Personalized therapy in pain management: where do we stand?. Pharmacogenomics 11:6, 843-864
CrossRef46
Ruth Landau, John C Kraft. (2010) Pharmacogenetics in obstetric anesthesia. Current Opinion in Anaesthesiology 23:3, 323-329
CrossRef47
CF Samer, Y Daali, M Wagner, G Hopfgartner, CB Eap, MC Rebsamen, MF Rossier, D Hochstrasser, P Dayer, JA Desmeules. (2010) The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. British Journal of Pharmacology 160:4, 907-918
CrossRef48
Ruth Landau. (2010) Pharmacogenetic influences in obstetric anaesthesia. Best Practice & Research Clinical Obstetrics & Gynaecology 24:3, 277-287
CrossRef49
R.A. Moore, S. Derry, H.J. McQuay, S. Straube, D. Aldington, P. Wiffen, R.F. Bell, E. Kalso, M.C. Rowbotham. (2010) Clinical effectiveness: An approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. PAIN 149:2, 173-176
CrossRef50
Michael R. Bleavins, Claudio Carini, Malle Jurima-Romet, Ramin Rahbari. 2010. Biomarkers. .
CrossRef51
M. Kato, T. Kawaguchi, S. Ishikawa, T. Umeda, R. Nakamichi, M. H. Shapero, K. W. Jones, Y. Nakamura, H. Aburatani, T. Tsunoda. (2010) Population-genetic nature of copy number variations in the human genome. Human Molecular Genetics 19:5, 761-773
CrossRef52
Henry McQuay. 2010. Drug Treatment of Chronic Pain. , 424-433.
CrossRef53
Liewei Wang. (2010) Pharmacogenomics: a systems approach. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 2:1, 3-22
CrossRef54
S Willmann, A N Edginton, K Coboeken, G Ahr, J Lippert. (2009) Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study. Clinical Pharmacology & Therapeutics 86:6, 634-643
CrossRef55
Gabriel A Vargas. (2009) Personalized healthcare: how to improve outcomes by increasing benefit and decreasing risk through the use of biomarkers. Biomarkers in Medicine 3:6, 701-709
CrossRef56
Jörn Lötsch, Gerd Geisslinger, Irmgard Tegeder. (2009) Genetic modulation of the pharmacological treatment of pain. Pharmacology & Therapeutics 124:2, 168-184
CrossRef57
Elizabeth C. Kudzma, Eileen T. Carey. (2009) Pharmacogenomics: Personalizing Drug Therapy. AJN, American Journal of Nursing 109:10, 50-57
CrossRef58
Steven H. Y. Wong. 2009. Pharmacogenomics. .
CrossRef59
Irmgard Tegeder, Jörn Lötsch. (2009) Current evidence for a modulation of low back pain by human genetic variants. Journal of Cellular and Molecular Medicine 13:8b, 1605-1619
CrossRef60
Gary M Reisfield, Bruce A Goldberger, Roger L Bertholf. (2009) ‘False-positive’ and ‘false-negative’ test results in clinical urine drug testing. Bioanalysis 1:5, 937-952
CrossRef61
Jörn Lötsch, Maren Rohrbacher, Helmut Schmidt, Alexandra Doehring, Jürgen Brockmöller, Gerd Geisslinger. (2009) Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?. PAIN 144:1-2, 119-124
CrossRef62
Caroline F. Thorn, Teri E. Klein, Russ B. Altman. (2009) Codeine and morphine pathway. Pharmacogenetics and Genomics 19:7, 556-558
CrossRef63
Maren Hermanns-Clausen, Wolfgang Weinmann, Volker Auwärter, Nerea Ferreirós, Rainer Trittler, Christoph Müller, Andreas Pahl, Andrea Superti-Furga, Roland Hentschel. (2009) Drug dosing error with drops—severe clinical course of codeine intoxication in twins. European Journal of Pediatrics 168:7, 819-824
CrossRef64
Howard S. Smith. (2009) Opioid Metabolism. Mayo Clinic Proceedings 84:7, 613-624
CrossRef65
H. S. Smith. (2009) Opioid Metabolism. Mayo Clinic Proceedings 84:7, 613-624
CrossRef66
F. Wickham Kraemer, John B. Rose. (2009) Pharmacologic Management of Acute Pediatric Pain. Anesthesiology Clinics 27:2, 241-268
CrossRef67
Nada Božina, Vlasta Bradamante, Mila Lovrić. (2009) Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk. Archives of Industrial Hygiene and Toxicology 60:2, 217-242
CrossRef68
Jörn Lötsch, Nils von Hentig, Rainer Freynhagen, Norbert Griessinger, Michael Zimmermann, Alexandra Doehring, Maren Rohrbacher, Reinhard Sittl, Gerd Geisslinger. (2009) Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenetics and Genomics 19:6, 429-436
CrossRef69
Isabel Spriet, Wouter Meersseman, Jan Hoon, Sandrina Winckelmann, Alexander Wilmer, Ludo Willems. (2009) Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Medicine 35:4, 603-612
CrossRef70
Stéphane Mouly, Christophe Meune, Jean-François Bergmann. (2009) Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4. Intensive Care Medicine 35:3, 417-429
CrossRef71
Michael L. LaCroix-Fralish, Jeffrey S. Mogil. (2009) Progress in Genetic Studies of Pain and Analgesia. Annual Review of Pharmacology and Toxicology 49:1, 97-121
CrossRef72
Janet K. Coller, Lona L. Christrup, Andrew A. Somogyi. (2009) Role of active metabolites in the use of opioids. European Journal of Clinical Pharmacology 65:2, 121-139
CrossRef73
M C Rebsamen, J Desmeules, Y Daali, A Chiappe, A Diemand, C Rey, J Chabert, P Dayer, D Hochstrasser, M F Rossier. (2009) The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. The Pharmacogenomics Journal 9:1, 34-41
CrossRef74
J Lötsch, K Flühr, T Neddermayer, A Doehring, G Geisslinger. (2009) The Consequence of Concomitantly Present Functional Genetic Variants for the Identification of Functional Genotype–Phenotype Associations in Pain. Clinical Pharmacology & Therapeutics 85:1, 25-30
CrossRef75
P Madadi, CJD Ross, MR Hayden, BC Carleton, A Gaedigk, JS Leeder, G Koren. (2009) Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Case–Control Study. Clinical Pharmacology & Therapeutics 85:1, 31-35
CrossRef76
Yusuke Nakamura. (2009) DNA variations in human and medical genetics: 25 years of my experience. Journal of Human Genetics 54:1, 1-8
CrossRef77
José de Leon, Maria J. Arranz, Gualberto Ruaño. (2008) Pharmacogenetic Testing in Psychiatry: A Review of Features and Clinical Realities. Clinics in Laboratory Medicine 28:4, 599-617
CrossRef78
Wendell W. Weber. (2008) Pharmacogenetics: From Description to Prediction. Clinics in Laboratory Medicine 28:4, 499-511
CrossRef79
Simon Challand, Katie Frew, Claud Regnard. (2008) Is There A Problem with Oxycodone?. Journal of Pain and Symptom Management 36:6, e1-e3
CrossRef80
Jerry H. Kim, Debra A. Schwinn, Ruth Landau. (2008) Pharmacogenomics and perioperative medicine — Implications for modern clinical practice. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 55:12, 799-806
CrossRef81
Kristen K. Reynolds, Bronwyn Ramey-Hartung, Saeed A. Jortani. (2008) The Value of CYP2D6 and OPRM1 Pharmacogenetic Testing for Opioid Therapy. Clinics in Laboratory Medicine 28:4, 581-598
CrossRef82
Ruth Landau. (2008) Pharmacogenetics and Obstetric Anesthesia. International Anesthesiology Clinics 45:1, 1-15
CrossRef83
Ulrich M. Zanger, Miia Turpeinen, Kathrin Klein, Matthias Schwab. (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and Bioanalytical Chemistry 392:6, 1093-1108
CrossRef84
R. E. Ferner. (2008) Post-mortem clinical pharmacology. British Journal of Clinical Pharmacology 66:4, 430-443
CrossRef85
K. Allegaert, J.N. van den Anker. (2008) How to use drugs for pain management: from pharmacokinetics to pharmacogenomics. European Journal of Pain Supplements 2:1, 25-30
CrossRef86
Randolph S. Faustino, Anca Chiriac, Andre Terzic. (2008) Bioinformatic Primer for Clinical and Translational Science. Clinical and Translational Science 1:2, 174-180
CrossRef87
Parvaz Madadi, Gideon Koren. (2008) Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics 9:9, 1267-1284
CrossRef88
Ulrike M. Stamer, Frank Stüber, Thomas Muders, Frank Musshoff. (2008) Respiratory Depression with Tramadol in a Patient with Renal Impairment and CYP2D6 Gene Duplication. Anesthesia & Analgesia 107:3, 926-929
CrossRef89
MG Buzzi. (2008) Pathways to the best fit of triptans for migraine patients. Cephalalgia 28, 21-27
CrossRef90
Marie Besson, Valérie Piguet, Pierre Dayer, Jules Desmeules. (2008) New approaches to the pharmacotherapy of neuropathic pain. Expert Review of Clinical Pharmacology 1:5, 683-693
CrossRef91
Patrice Forget, Bernard le Polain de Waroux, Pierre Wallemacq, Jean-Luc Gala. (2008) Life-Threatening Dextromethorphan Intoxication Associated with Interaction with Amitriptyline in a Poor CYP2D6 Metabolizer: A Single Case Re-Exposure Study. Journal of Pain and Symptom Management 36:1, 92-96
CrossRef92
Victoria Rollason, Caroline Samer, Valerie Piguet, Pierre Dayer, Jules Desmeules. (2008) Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 9:7, 905-933
CrossRef93
Shinya Kasai, Masakazu Hayashida, Ichiro Sora, Kazutaka Ikeda. (2008) Candidate gene polymorphisms predicting individual sensitivity to opioids. Naunyn-Schmiedeberg's Archives of Pharmacology 377:4-6, 269-281
CrossRef94
Costas Ioannides. 2008. Xenobiotic Metabolism. .
CrossRef95
Matthew E. Hurles, Emmanouil T. Dermitzakis, Chris Tyler-Smith. (2008) The functional impact of structural variation in humans. Trends in Genetics 24:5, 238-245
CrossRef96
Kyohei Otani, Hiroshi Ujike, Ayumu Sakai, Yuko Okahisa, Tatsuya Kotaka, Toshiya Inada, Mutsuo Harano, Tokutaro Komiyama, Toru Hori, Mitsuhiko Yamada. (2008) Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence. Neuroscience Letters 434:1, 88-92
CrossRef97
Jose de Leon. (2008) CYP2D6 genotyping and codeine. Pediatric Anesthesia 18:3, 274-275
CrossRef98
Kirk J. Mantione, Patrick Cadet, Wei Zhu, Richard M. Kream, Melinda Sheehan, Gregory L. Fricchione, Yannick Goumon, Tobias Esch, George B. Stefano. (2008) Endogenous morphine signaling via nitric oxide regulates the expression of CYP2D6 and COMT: autocrine/paracrine feedback inhibition. Addiction Biology 13:1, 118-123
CrossRef99
S. N. De Wildt, G. Koren. (2008) Authors' reply. Pediatric Anesthesia 18:3, 273-274
CrossRef100
Donna L. Mendrick. (2008) Genomic and genetic biomarkers of toxicity. Toxicology 245:3, 175-181
CrossRef101
Ruth Landau. (2008) Pharmacogenetics and Obstetric Anesthesia. Anesthesiology Clinics 26:1, 183-195
CrossRef102
Ulrike M. Stamer, Frank Stüber. (2008) Codeine induced respiratory depression in a child. Pediatric Anesthesia 18:3, 272-273
CrossRef103
Julia Kirchheiner, Jan-Tobias H.A. Keulen, Steffen Bauer, Ivar Roots, Jürgen Brockmöller. (2008) Effects of the CYP2D6 Gene Duplication on the Pharmacokinetics and Pharmacodynamics of Tramadol. Journal of Clinical Psychopharmacology 28:1, 78-83
CrossRef104
Bruno Oertel, Jörn Lötsch. (2008) Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics 9:2, 179-194
CrossRef105
CT Dollery. (2008) Clinical Pharmacology in the Molecular Era. Clinical Pharmacology & Therapeutics 83:2, 220-225
CrossRef106
Naoya Hosono, Michiaki Kubo, Yumiko Tsuchiya, Hiroko Sato, Takuya Kitamoto, Susumu Saito, Yozo Ohnishi, Yusuke Nakamura. (2008) Multiplex PCR-based real-time invader assay (mPCR-RETINA): a novel SNP-based method for detecting allelic asymmetries within copy number variation regions. Human Mutation 29:1, 182-189
CrossRef107
Kye-Min Kim. (2008) Pharmacogenetics of anesthetics. Korean Journal of Anesthesiology 55:5, 527
CrossRef108
Luda Diatchenko, Andrea G. Nackley, Inna E. Tchivileva, Svetlana A. Shabalina, William Maixner. (2007) Genetic architecture of human pain perception. Trends in Genetics 23:12, 605-613
CrossRef109
U. M. Stamer, F. Stüber. (2007) Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype. Anaesthesia 62:12, 1294-1295
CrossRef110
P.-H. Beaune. (2007) La pharmacogénétique : de la recherche fondamentale aux applications cliniques. Annales Pharmaceutiques Françaises 65:6, 365-370
CrossRef111
Ulrike M Stamer, Frank StÜber. (2007) The pharmacogenetics of analgesia. Expert Opinion on Pharmacotherapy 8:14, 2235-2245
CrossRef112
Ulrike M Stamer, Frank Stüber. (2007) Genetic factors in pain and its treatment. Current Opinion in Anaesthesiology 20:5, 478-484
CrossRef113
J Kirchheiner, H Schmidt, M Tzvetkov, J-Tha Keulen, J Lötsch, I Roots, J Brockmöller. (2007) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. The Pharmacogenomics Journal 7:4, 257-265
CrossRef114
POLINA VORONOV, HENRY J PRZYBYLO, NARASIMHAN JAGANNATHAN. (2007) Apnea in a child after oral codeine: a genetic variant ? an ultra-rapid metabolizer. Pediatric Anesthesia 17:7, 684-687
CrossRef115
POLINA VORONOV, HENRY J PRZYBYLO, NARASIMHAN JAGANNATHAN. (2007) Apnea in a child after oral codeine: a genetic variant ? an ultra-rapid metabolizer. Pediatric Anesthesia 0:0, 070410014202001-???
CrossRef116
A W Jones, A Holmgren, F C Kugelberg. (2007) Concentrations of Scheduled Prescription Drugs in Blood of Impaired Drivers: Considerations for Interpreting the Results. Therapeutic Drug Monitoring 29:2, 248-260
CrossRef117
D. Frank, U. Jaehde, U. Fuhr. (2007) Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. European Journal of Clinical Pharmacology 63:4, 321-333
CrossRef118
Colin J.D. Ross, Hagit Katzov, Bruce Carleton, Michael R. Hayden. (2007) Pharmacogenomics and its implications for autoimmune disease. Journal of Autoimmunity 28:2-3, 122-128
CrossRef119
Andrew A Somogyi, Daniel T Barratt, Janet K Coller. (2007) Pharmacogenetics of Opioids. Clinical Pharmacology & Therapeutics 81:3, 429-444
CrossRef120
Pieter W. Troost, Bertine E. Lahuis, Mirjam H. Hermans, Jan K. Buitelaar, Herman van Engeland, Lawrence Scahill, Ruud B. Minderaa, Pieter J. Hoekstra. (2007) Prolactin Release in Children Treated With Risperidone. Journal of Clinical Psychopharmacology 27:1, 52-57
CrossRef121
John L Black III, Dennis J O’Kane, David A Mrazek. (2007) The impact of CYP allelic variation on antidepressant metabolism: a review. Expert Opinion on Drug Metabolism & Toxicology 3:1, 21-31
CrossRef122
Richard M. Weinshilboum, Liewei Wang. (2006) Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. Annual Review of Genomics and Human Genetics 7:1, 223-245
CrossRef123
Margaret T. Susce, Elaina Murray-Carmichael, Jose de Leon. (2006) Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30:7, 1356-1358
CrossRef124
Caroline Flora Samer, Jules Alexandre Desmeules, Pierre Dayer. (2006) Individualizing analgesic prescription Part I: pharmacogenetics of opioid analgesics. Personalized Medicine 3:3, 239-269
CrossRef125
Richard M. Langford. (2006) Pain management today—what have we learned?. Clinical Rheumatology 25:S1, 2-8
CrossRef126
U. Stamer, B. Bayerer, F. Stüber. (2006) Genetik, Schmerz und Analgesie. Der Anaesthesist 55:7, 746-752
CrossRef127
William Clarke, Gwen McMillin. (2006) Application of TDM, pharmacogenomics and biomarkers for neurological disease pharmacotherapy: focus on antiepileptic drugs. Personalized Medicine 3:2, 139-149
CrossRef128
Loralie J. Langman, Bhushan M. Kapur. (2006) Toxicology: Then and now. Clinical Biochemistry 39:5, 498-510
CrossRef129
Mark A. Warner. (2006) Who Better Than Anesthesiologists?. Anesthesiology 104:5, 1094-1101
CrossRef130
Piotr K. Janicki, H Gregg Schuler, Tomasz M. Jarzembowski, Malina Rossi. (2006) Prevention of Postoperative Nausea and Vomiting with Granisetron and Dolasetron in Relation to CYP2D6 Genotype. Anesthesia & Analgesia 102:4, 1127-1133
CrossRef131
Jörn Lötsch, Gerd Geisslinger. (2006) Current evidence for a genetic modulation of the response to analgesics. Pain 121:1-2, 1-5
CrossRef132
Eveline Jaquenoud Sirot, Jan Willem van der Velden, Katharina Rentsch, Chin B Eap, Pierre Baumann. (2006) Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance. Drug Safety 29:9, 735-768
CrossRef133
Richard J. Bodnar, Gad E. Klein. (2005) Endogenous opiates and behavior: 2004. Peptides 26:12, 2629-2711
CrossRef134
Hong-Guang Xie, Felix W Frueh. (2005) Pharmacogenomics steps toward personalized medicine. Personalized Medicine 2:4, 325-337
CrossRef135
Caroline F. Samer, Valérie Piguet, Pierre Dayer, Jules A. Desmeules. (2005) Polymorphisme génétique et interactions médicamenteuses : leur importance dans le traitement de la douleur. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 52:8, 806-821
CrossRef136
R LANDAU. (2005) Pharmacogenetics: implications for obstetric anesthesia. International Journal of Obstetric Anesthesia 14:4, 316-323
CrossRef137
M. Ingelman-Sundberg, C. Rodriguez-Antona. (2005) Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philosophical Transactions of the Royal Society B: Biological Sciences 360:1460, 1563-1570
CrossRef138
K.-H. Le Quan Sang, M. Levacher, J.-C. Thalabard. (2005) Liens métaboliques entre la codéine et la morphine. Science & Sports 20:4, 218-221
CrossRef139
Barkur S. Shastry. (2005) Genetic diversity and new therapeutic concepts. Journal of Human Genetics 50:7, 321-328
CrossRef140
Kathryn A. Phillips, Stephanie L. Van Bebber. (2005) Measuring the value of pharmacogenomics. Nature Reviews Drug Discovery 4:6, 500-509
CrossRef141
Wilkinson, Grant R., . (2005) Drug Metabolism and Variability among Patients in Drug Response. New England Journal of Medicine 352:21, 2211-2221
Full Text142
A. Li Wan Po. (2005) Drug-drug interactions and adverse drug reactions: the bollards and flashing lights syndrome. Journal of Clinical Pharmacy and Therapeutics 30:2, 97-99
CrossRef143
Caraco, Yoseph, . (2004) Genes and the Response to Drugs. New England Journal of Medicine 351:27, 2867-2869
Full Text
